Atossa Genetics Inc (ATOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Atossa Genetics Inc (ATOS) has a cash flow conversion efficiency ratio of -0.121x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.00 Million) by net assets ($49.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ATOS net asset quality index to measure how much of total assets are equity-financed.
Atossa Genetics Inc - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Atossa Genetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Atossa Genetics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Atossa Genetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atossa Genetics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Noxopharm Ltd
AU:NOX
|
2.404x |
|
DAIHAN Scientific Co. Ltd
KQ:131220
|
0.006x |
|
PS International Group Ltd. Ordinary Shares
NASDAQ:PSIG
|
0.046x |
|
Moorim SP Co. Ltd
KQ:001810
|
-0.006x |
|
DUKE Robotics Corp. Common Stock
NASDAQ:DUKR
|
0.902x |
|
Alphawave IP Group PLC
LSE:AWE
|
-0.107x |
|
Eagon Ind
KO:008250
|
0.033x |
|
Steady Safe TBK PT
JK:SAFE
|
0.359x |
Annual Cash Flow Conversion Efficiency for Atossa Genetics Inc (2009–2024)
The table below shows the annual cash flow conversion efficiency of Atossa Genetics Inc from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see ATOS market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $71.48 Million | $-21.03 Million | -0.294x | -27.88% |
| 2023-12-31 | $91.02 Million | $-20.94 Million | -0.230x | -30.74% |
| 2022-12-31 | $117.96 Million | $-20.76 Million | -0.176x | -47.58% |
| 2021-12-31 | $138.14 Million | $-16.47 Million | -0.119x | +72.00% |
| 2020-12-31 | $27.17 Million | $-11.57 Million | -0.426x | +38.62% |
| 2019-12-31 | $13.16 Million | $-9.13 Million | -0.694x | +31.83% |
| 2018-12-31 | $8.81 Million | $-8.96 Million | -1.018x | -7.10% |
| 2017-12-31 | $6.94 Million | $-6.59 Million | -0.950x | +45.24% |
| 2016-12-31 | $3.10 Million | $-5.37 Million | -1.735x | +53.46% |
| 2015-12-31 | $3.74 Million | $-13.95 Million | -3.729x | -235.56% |
| 2014-12-31 | $9.50 Million | $-10.56 Million | -1.111x | -33.43% |
| 2013-12-31 | $10.60 Million | $-8.83 Million | -0.833x | -10.53% |
| 2012-12-31 | $5.18 Million | $-3.90 Million | -0.754x | +66.35% |
| 2011-12-31 | $1.56 Million | $-3.49 Million | -2.239x | -632.62% |
| 2010-12-31 | $-851.85K | $-358.11K | 0.420x | +117.72% |
| 2009-12-31 | $31.68K | $-75.18K | -2.373x | -- |
About Atossa Genetics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develop… Read more